Abstract Library

#4550 The relationship between MEN1 germline mutations and SSTR2 expression in neuroendocrine tumours

Introduction: Multiple endocrine neoplasia type 1 (MEN1) is a rare hereditary disease characterised by the development of multiglandular parathyroid disease, pituitary tumours, and duodenopancreatic neuroendocrine tumours (NETs). Germline mutations in the tumour suppressor gene MEN1 are the underlying cause. Somatostatin receptor 2 (SSTR2) is commonly expressed by NETs. However, the expression of SSTR2 in patients with MEN1 remains unclear.

Conference:

Presenting Author: Chi Y

Authors: Sun Y, Tan H, Wang H, Shi S, Dong L,

Keywords: multiple endocrine neoplasia type 1, somatostatin receptor 2, neuroendocrine tumour,

#4188 A case report of metastatic mediastinal MiNEN with clinical complete remission

Introduction: Because of diversity and heterogeneity of tumor pathological components, MiNEN have certain different clinical drug choices and clinical outcomes compared with neuroendocrine tumors.

Conference:

Presenting Author: Tan H

Authors: Tan H, Zhao H, Jiang L, Shi S, Zhao J,

Keywords: metastatic mediastinal MiNEN, clinical complete remission,

#4170 Analysis of the efficacy of STEM chemotherapy in patients with metastatic paraganglioma

Introduction: Paraganglioma is a special kind of neuroendocrine tumor, located outside the adrenal gland, about 35-40% is related to heredity and has corresponding germline mutation. The therapeutic response is different from that of neuroendocrine tumors derived from gastrointestinal and pancreas.

Conference:

Presenting Author: Tan H

Authors: Tan H, Zhao H, Shi S, Jiang L, Chi Y,

Keywords: metastatic paraganglioma, STEM, efficacy,

#4108 Clinical and epidemiological profile of neuroendocrine differentiation – A hospital-based retrospective study

Introduction: Global research on neuroendocrine differentiation (NED) in carcinomas remains limited, despite its distinct clinical features, disease progression, pathology, treatment outcomes, and poor prognosis. At the 2023 ENETS Conference, we presented our findings on NED in gastric cancer and colorectal cancer. However, more studies are essential to better comprehend NED's clinical and epidemiological aspects.

Conference:

Presenting Author:

Authors: Wen Y, Shi S,

Keywords: Neuroendocrine differentiation, breast cancer, lung cancer, esophageal cancer, prostate cancer,

#3806 Epidemiologic study of neuroendocrine differentiation in different carcinomas

Introduction: Carcinomas with neuroendocrine differentiation (NED) are characterized by clinical manifestations, pathological changes, treatment responses and poor prognosis. But there are few studies around the world currently. Further analysis of large clinical samples is still needed to reveal its biological characteristics and clarify the diagnosis and treatment of NED.

Conference:

Presenting Author:

Authors: Wen Y, Shi S,

Keywords: Neuroendocrine differentiation, individualized treatment, colorectal cancer, gastric cancer,